What are the criteria for diagnosing Chronic Lymphocytic Leukemia (CLL) on a peripheral smear?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnostic Criteria for CLL on Peripheral Smear

The diagnosis of CLL on peripheral smear requires small, mature-appearing lymphocytes with narrow cytoplasm borders and dense nuclei lacking discernible nucleoli with partially aggregated chromatin, accompanied by an absolute lymphocyte count ≥5,000/µL sustained for at least 3 months. 1

Morphologic Features on Blood Smear

The characteristic cells you should identify include:

  • Small, mature lymphocytes with a narrow border of cytoplasm 1
  • Dense nucleus lacking discernible nucleoli 1
  • Partially aggregated chromatin pattern 1
  • Smudge cells (nuclear shadows from ruptured lymphocytes) are characteristic but not required for diagnosis 2

Important Morphologic Caveats

  • Larger atypical lymphocytes or prolymphocytes may be present but must not exceed 55% of the lymphocyte population 1
  • If prolymphocytes exceed 55% OR absolute prolymphocyte count exceeds 15,000/µL, this establishes a diagnosis of prolymphocytic leukemia (PLL) rather than CLL 1

Quantitative Threshold

The absolute lymphocyte count must be ≥5,000 monoclonal B lymphocytes/µL in peripheral blood 1

Duration Requirement

  • The lymphocytosis must be sustained for at least 3 months to distinguish CLL from transient reactive lymphocytosis 1
  • In the 1996 NCI guidelines, only patients with questionable or indolent presentations required reassessment after 4 weeks 1

Essential Confirmatory Testing

Flow cytometry is mandatory to confirm B-cell clonality and establish the diagnosis—the peripheral smear alone is insufficient 1, 3

The characteristic immunophenotype includes:

  • CD5+, CD19+, CD20+ (low), CD23+ co-expression 1, 3
  • Low surface immunoglobulin, CD20, and CD79b expression compared to normal B cells 1
  • Monoclonal light chain restriction (either kappa or lambda, not both) 1

Critical Differential Diagnosis

When you see CD5+ lymphocytes on smear, you must distinguish CLL from:

Mantle Cell Lymphoma

  • CD23 is typically negative in mantle cell lymphoma (versus positive in CLL) 1
  • If CD23 is positive, perform cyclin D1 staining or FISH for t(11;14) translocation to exclude mantle cell lymphoma 1

Small Lymphocytic Lymphoma (SLL)

  • SLL has the same morphology and immunophenotype as CLL but lymphocyte count is <5,000/µL 1, 3
  • SLL requires lymphadenopathy and/or splenomegaly for diagnosis 1

Common Pitfalls to Avoid

  • Do not diagnose CLL based on morphology alone—flow cytometry confirmation of clonality is essential 1, 3
  • Do not confuse reactive lymphocytosis with CLL—the 3-month duration requirement and flow cytometry prevent this error 1
  • Do not miss mantle cell lymphoma—always check CD23 expression when evaluating CD5+ lymphocytes 1
  • Do not overlook prolymphocyte percentage—exceeding 55% changes the diagnosis to PLL 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Clinical Significance of Smudge Cells in Chronic Lymphocytic Leukemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diagnostic Approach for Chronic Lymphocytic Leukemia (CLL)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.